Norges Bank Acquires Shares of 1,127,468 OPKO Health, Inc. (NASDAQ:OPK)

Norges Bank purchased a new stake in OPKO Health, Inc. (NASDAQ:OPK - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,127,468 shares of the biotechnology company's stock, valued at approximately $1,657,000. Norges Bank owned 0.17% of OPKO Health at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Barclays PLC grew its stake in shares of OPKO Health by 154.5% in the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company's stock valued at $810,000 after buying an additional 329,870 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of OPKO Health by 736.7% during the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company's stock valued at $368,000 after purchasing an additional 217,450 shares during the last quarter. FMR LLC lifted its stake in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after buying an additional 11,089 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of OPKO Health during the fourth quarter valued at approximately $221,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in OPKO Health during the 4th quarter worth $102,000. Institutional investors and hedge funds own 64.63% of the company's stock.

Insider Buying and Selling

In other news, CEO Phillip Md Et Al Frost acquired 150,000 shares of the firm's stock in a transaction dated Friday, January 17th. The stock was bought at an average cost of $1.47 per share, for a total transaction of $220,500.00. Following the completion of the transaction, the chief executive officer now directly owns 213,186,477 shares in the company, valued at $313,384,121.19. This represents a 0.07 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders purchased 964,971 shares of company stock valued at $1,528,692. Company insiders own 49.69% of the company's stock.

OPKO Health Trading Down 0.4 %

NASDAQ OPK traded down $0.01 during trading on Thursday, reaching $1.42. 494,821 shares of the stock traded hands, compared to its average volume of 4,647,491. OPKO Health, Inc. has a fifty-two week low of $1.15 and a fifty-two week high of $2.04. The stock's 50-day moving average price is $1.68 and its 200 day moving average price is $1.57. The firm has a market cap of $950.24 million, a price-to-earnings ratio of -7.45 and a beta of 1.78. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm had revenue of $183.60 million for the quarter, compared to analysts' expectations of $155.42 million. Analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Barrington Research restated an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research report on Wednesday, March 12th. StockNews.com upgraded OPKO Health from a "sell" rating to a "hold" rating in a research note on Monday, March 3rd. Finally, HC Wainwright reaffirmed a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research report on Monday, April 7th.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.